SpectraCure (Sweden) Performance
| SPEC Stock | SEK 0.09 0.01 6.70% |
The entity has a beta of 0.58, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, SpectraCure's returns are expected to increase less than the market. However, during the bear market, the loss of holding SpectraCure is expected to be smaller as well. At this point, SpectraCure AB has a negative expected return of -1.01%. Please make sure to validate SpectraCure's standard deviation, total risk alpha, maximum drawdown, as well as the relationship between the jensen alpha and treynor ratio , to decide if SpectraCure AB performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days SpectraCure AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 157.2 M | |
| Total Cashflows From Investing Activities | -8.5 M |
SpectraCure |
SpectraCure Relative Risk vs. Return Landscape
If you would invest 18.00 in SpectraCure AB on October 31, 2025 and sell it today you would lose (8.67) from holding SpectraCure AB or give up 48.17% of portfolio value over 90 days. SpectraCure AB is generating negative expected returns and assumes 4.7839% volatility on return distribution over the 90 days horizon. Simply put, 42% of stocks are less volatile than SpectraCure, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
SpectraCure Target Price Odds to finish over Current Price
The tendency of SpectraCure Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.09 | 90 days | 0.09 | about 98.0 |
Based on a normal probability distribution, the odds of SpectraCure to move above the current price in 90 days from now is about 98.0 (This SpectraCure AB probability density function shows the probability of SpectraCure Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon SpectraCure has a beta of 0.58. This usually implies as returns on the market go up, SpectraCure average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding SpectraCure AB will be expected to be much smaller as well. Additionally SpectraCure AB has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. SpectraCure Price Density |
| Price |
Predictive Modules for SpectraCure
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as SpectraCure AB. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.SpectraCure Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. SpectraCure is not an exception. The market had few large corrections towards the SpectraCure's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold SpectraCure AB, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of SpectraCure within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.99 | |
β | Beta against Dow Jones | 0.58 | |
σ | Overall volatility | 0.03 | |
Ir | Information ratio | -0.2 |
SpectraCure Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of SpectraCure for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for SpectraCure AB can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| SpectraCure AB generated a negative expected return over the last 90 days | |
| SpectraCure AB has some characteristics of a very speculative penny stock | |
| SpectraCure AB has high historical volatility and very poor performance | |
| The company reported the revenue of 5.75 M. Net Loss for the year was (23.34 M) with profit before overhead, payroll, taxes, and interest of 2.99 M. | |
| SpectraCure AB has accumulated about 129.69 M in cash with (18.6 M) of positive cash flow from operations. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
SpectraCure Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of SpectraCure Stock often depends not only on the future outlook of the current and potential SpectraCure's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. SpectraCure's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 107.5 M | |
| Cash And Short Term Investments | 129.7 M |
SpectraCure Fundamentals Growth
SpectraCure Stock prices reflect investors' perceptions of the future prospects and financial health of SpectraCure, and SpectraCure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on SpectraCure Stock performance.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.0851 | |||
| Operating Margin | (15.50) % | |||
| Current Valuation | 561.51 M | |||
| Shares Outstanding | 97.13 M | |||
| Price To Book | 4.21 X | |||
| Price To Sales | 396.86 X | |||
| Revenue | 5.75 M | |||
| EBITDA | (20.43 M) | |||
| Cash And Equivalents | 129.69 M | |||
| Total Debt | 2.49 M | |||
| Book Value Per Share | 1.61 X | |||
| Cash Flow From Operations | (18.6 M) | |||
| Earnings Per Share | (0.26) X | |||
| Total Asset | 190.52 M | |||
| Retained Earnings | (14 M) | |||
| Current Asset | 5 M | |||
| Current Liabilities | 3 M | |||
About SpectraCure Performance
Assessing SpectraCure's fundamental ratios provides investors with valuable insights into SpectraCure's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the SpectraCure is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about SpectraCure AB performance evaluation
Checking the ongoing alerts about SpectraCure for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for SpectraCure AB help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| SpectraCure AB generated a negative expected return over the last 90 days | |
| SpectraCure AB has some characteristics of a very speculative penny stock | |
| SpectraCure AB has high historical volatility and very poor performance | |
| The company reported the revenue of 5.75 M. Net Loss for the year was (23.34 M) with profit before overhead, payroll, taxes, and interest of 2.99 M. | |
| SpectraCure AB has accumulated about 129.69 M in cash with (18.6 M) of positive cash flow from operations. | |
| Roughly 21.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing SpectraCure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether SpectraCure's stock is overvalued or undervalued compared to its peers.
- Examining SpectraCure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating SpectraCure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of SpectraCure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of SpectraCure's stock. These opinions can provide insight into SpectraCure's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for SpectraCure Stock Analysis
When running SpectraCure's price analysis, check to measure SpectraCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SpectraCure is operating at the current time. Most of SpectraCure's value examination focuses on studying past and present price action to predict the probability of SpectraCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SpectraCure's price. Additionally, you may evaluate how the addition of SpectraCure to your portfolios can decrease your overall portfolio volatility.